Intellia Therapeutics, Inc.
NTLA- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001652130
In the last 90 days, Intellia Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 329 institutions reported holding it in 13F filings for Q2 2026, worth $2.43B in total; ARK Invest is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Intellia Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 4 filings
- 3 insiders, $506.6K in total
- Insiders trading
- 3
- Net value
- −$506.6K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Intellia Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Leonard John M | President and CEO | 1,147,064 | Aug 24, 2026 | 4 |
| Dulac Edward J III | EVP, Chief Financial Officer | 148,175 | Jul 24, 2026 | 4 |
| Dube Michael P | VP, Chief Accounting Officer | 66,886 | Jul 6, 2026 | 4 |
| Cohen Fred E | Director | 216,653 | Jun 10, 2026 | 2 |
| Verwiel Frank | Director | 35,148 | Jun 10, 2026 | 1 |
| Goff Brian | Director | 32,609 | Jun 10, 2026 | 1 |
| Chase William J | Director | 143,893 | Jun 10, 2026 | 1 |
| Goodman Jesse | Director | 33,559 | Jun 10, 2026 | 1 |
| Keresty Georgia | Director | 41,083 | Jun 10, 2026 | 1 |
| Bhanji Muna | Director | 36,403 | Jun 10, 2026 | 1 |
| Basta James | EVP, General Counsel | 156,794 | Mar 3, 2026 | 2 |
| Lebwohl David | EVP, Chief Medical Officer | 131,192 | Mar 3, 2026 | 2 |
| Clark Eliana | EVP, Chief Technical Officer | 93,864 | Mar 3, 2026 | 2 |
| Schultes Birgit C | EVP, Chief Scientific Officer | 137,733 | Mar 3, 2026 | 3 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 77,388 | Jan 7, 2025 | 0 |
| Hicks Derek | EVP, Chief Business Officer | 59,878 | Jan 7, 2025 | 0 |
| Goddard Glenn | EVP, Chief Financial Officer | 69,213 | Mar 5, 2024 | 0 |
| Crowley John F | Director | 11,716 | Jun 16, 2023 | 0 |
| Formela Jean Francois | Director | 7,291 | Jun 16, 2022 | 0 |
| Dorsa Caroline | Director | 12,701 | Jun 16, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 22, 2023 (view filing) | Jun 20 | 2 days | Clark ElianaEVP, Chief Technical Officer | SSale | −5.00K | $45.00 | −$225.0K | −10.0%45.1K after | 10b5-1 |
| Mar 3, 2023 (view filing) | Mar 2 | 1 day | Basta JamesEVP, General Counsel | SSale | −1.09K | $43.88 | −$47.7K | −1.9%55.3K after | |
| Jan 6, 2023 (view filing) | Jan 4-5 | 2 days | Sepp-Lorenzino LauraEVP, Chief Scientific Officer | SSale | −4.84K | $37.82 | −$183.0K | −21.5%17.6K after | 3 lots |
| Jan 6, 2023 (view filing) | Jan 4 | 2 days | Leonard John MPresident and CEO | SSale | −6.67K | $37.21 | −$248.3K | −0.9%766.8K after | |
| Jan 6, 2023 (view filing) | Jan 4 | 2 days | Hicks DerekEVP, Chief Business Officer | SSale | −1.81K | $37.21 | −$67.4K | −9.5%17.3K after | |
| Jan 6, 2023 (view filing) | Jan 4 | 2 days | Lebwohl DavidEVP, Chief Medical Officer | SSale | −2.57K | $37.21 | −$95.8K | −9.1%25.7K after | |
| Jan 6, 2023 (view filing) | Jan 4 | 2 days | Goddard GlennEVP, Chief Financial Officer | SSale | −2.43K | $37.21 | −$90.3K | −13.6%15.4K after | |
| Jan 6, 2023 (view filing) | Jul 1, 2022-Jan 4, 2023 | 189 daysLate | Clark ElianaEVP, Chief Technical Officer | SSale | −2.03K | $37.65 | −$76.4K | −12.3%14.5K after | 3 lots |
| Jan 6, 2023 (view filing) | Jan 4 | 2 days | Basta JamesEVP, General Counsel | SSale | −1.14K | $37.21 | −$42.3K | −5.5%19.6K after | |
| Mar 4, 2022 (view filing) | Jan 1 | 62 daysLate | Leonard John MPresident and CEO | SSale | −2.49K | $112.26 | −$279.9K | −0.3%724.7K after | |
| Mar 3, 2022 (view filing) | Jan 1 | 61 days | Goddard GlennEVP, Chief Financial Officer | SSale | −1.01K | $112.24 | −$113.7K | −33.1%2.05K after | From original |
| Mar 3, 2022 (view filing) | Jan 1 | 61 days | Lebwohl DavidEVP, Chief Medical Officer | SSale | −1.05K | $112.24 | −$118.0K | −8.8%10.9K after | From original |
| Mar 3, 2022 (view filing) | Jan 1 | 61 days | Sepp-Lorenzino LauraEVP, Chief Scientific Officer | SSale | −1.15K | $112.25 | −$128.9K | −19.3%4.82K after | From original |
| Nov 9, 2021 (view filing) | Nov 5 | 4 days | Lebwohl DavidEVP, Chief Medical Officer | SSale | −2.40K | $132.72 | −$318.5K | −21.6%8.71K after | 4 lots |
| Oct 15, 2021 (view filing) | Oct 14 | 1 day | Lebwohl DavidEVP, Chief Medical Officer | SSale | −2.40K | $128.44 | −$308.2K | −21.6%8.71K after | 5 lots |
| Oct 13, 2021 (view filing) | Oct 11 | 2 days | Crowley John FDirector | SSale | −2.50K | $119.55 | −$298.9K | −54.4%2.09K after | |
| Oct 7, 2021 (view filing) | Oct 5 | 2 days | Crowley John FDirector | SSale | −10.0K | $130.54 | −$1.31M | −82.7%2.09K after | 5 lots |
| Sep 23, 2021 (view filing) | Sep 21 | 2 days | Lebwohl DavidEVP, Chief Medical Officer | SSale | −2.40K | $149.81 | −$359.5K | −75.2%791 after | |
| Sep 9, 2021 (view filing) | Sep 7 | 2 days | Goddard GlennEVP, Chief Financial Officer | SSale | −3.48K | $180.12 | −$627.2K | −100.0%0 after | |
| Sep 1, 2021 (view filing) | Aug 30-Sep 1 | 2 days | Leonard John MPresident and CEO | SSale | −121.4K | $160.83 | −$19.5M | −14.4%719.3K after | 11 lots |
| Sep 1, 2021 (view filing) | Aug 30 | 2 days | Sepp-Lorenzino LauraEVP, Chief Scientific Officer | SSale | −97.0K | $154.83 | −$15.0M | −97.6%2.39K after | 9 lots |
| Sep 1, 2021 (view filing) | Aug 30 | 2 days | Lebwohl DavidEVP, Chief Medical Officer | SSale | −2.40K | $158.04 | −$379.3K | −75.2%791 after | 5 lots |
| Sep 1, 2021 (view filing) | Aug 30-31 | 2 days | Goddard GlennEVP, Chief Financial Officer | SSale | −30.0K | $159.45 | −$4.78M | −100.0%0 after | 9 lots |
| Aug 25, 2021 (view filing) | Aug 23 | 2 days | Leonard John MPresident and CEO | SSale | −27.1K | $152.01 | −$4.13M | −3.6%719.3K after | 3 lots |
| Aug 20, 2021 (view filing) | Aug 19 | 1 day | Leonard John MPresident and CEO | SSale | −22.7K | $151.28 | −$3.43M | −3.1%719.3K after | 3 lots |
| Aug 11, 2021 (view filing) | Aug 9 | 2 days | Lebwohl DavidEVP, Chief Medical Officer | SSale | −2.40K | $164.05 | −$393.7K | −75.2%791 after | |
| Aug 6, 2021 (view filing) | Aug 4 | 2 days | Sepp-Lorenzino LauraEVP, Chief Scientific Officer | SSale | −26.0K | $138.24 | −$3.59M | −91.6%2.39K after | 7 lots |
| Aug 6, 2021 (view filing) | Aug 5 | 1 day | Goddard GlennEVP, Chief Financial Officer | SSale | −20.0K | $151.05 | −$3.02M | −100.0%0 after | 3 lots |